SEC Form 4 · accession 0001104659-16-159635

Amphastar Pharmaceuticals, Inc. · AMPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and General Counsel · Director

Period of report

Nov 25, 2016

Accepted (ET)

Nov 29, 2016 · 6:13 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001297184

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Nov 25, 2016	M	2,043	$10.93	A	205,004	D
Common Stock^F2	Nov 25, 2016	S	2,043	$20.5858	D	202,961	D
Common Stock	Nov 28, 2016	M	24,292	$10.93	A	227,253	D
Common Stock^F3	Nov 28, 2016	S	24,292	$20.4677	D	202,961	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$10.93	Nov 25, 2016	M	2,043	D	—	Jul 5, 2023	Common Stock	2,043	92,949	D
Employee Stock Option (right to buy)^F4	$10.93	Nov 28, 2016	M	24,292	D	—	Jul 5, 2023	Common Stock	24,292	68,657	D

F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2016.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.39 to $20.80 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.30 to $20.85, inclusive.
F4Shares subject to the option vest in four equal annual installments beginning on July 5, 2014.